Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Saved in:
| Title: | Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. |
|---|---|
| Authors: | Gomez-Roca, C A1 (AUTHOR) gomez-roca.carlos@iuct-oncopole.fr, Italiano, A2 (AUTHOR) a.italiano@bordeaux.unicancer.fr, Tourneau, C Le3,4,5 (AUTHOR), Cassier, P A6 (AUTHOR), Toulmonde, M2 (AUTHOR), D'Angelo, S P7,8 (AUTHOR), Campone, M9 (AUTHOR), Weber, K L10 (AUTHOR), Loirat, D3 (AUTHOR), Cannarile, M A11 (AUTHOR), Jegg, A -M11 (AUTHOR), Ries, C11 (AUTHOR), Christen, R12 (AUTHOR), Meneses-Lorente, G13 (AUTHOR), Jacob, W11 (AUTHOR), Klaman, I11 (AUTHOR), Ooi, C -H12 (AUTHOR), Watson, C14 (AUTHOR), Wonde, K12 (AUTHOR), Reis, B12 (AUTHOR) |
| Source: | Annals of Oncology. Aug2019, Vol. 30 Issue 8, p1381-1392. 12p. 2 Charts, 5 Graphs. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz163 |
